Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA1T66)

• Drug Name: YH010 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMA1T66

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukine 12 (IL-12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABP 654	DM0GXWT	Plaque psoriasis	EA90.0	Phase 3	[2]
Ad-RTS-hIL-12	DMCNTFW	Glioblastoma of brain	2A00.00	Phase 2	[3]
GEN-1	DMJN09S	Ovarian cancer	2C73	Phase 2	[4]
Tavokinogene telseplasmid	DMZX0VF	Melanoma	2C30	Phase 2	[5]
MEDI1191	DMD9OVI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
M9241	DMZUM67	Pancreatic cancer	2C10	Phase 1	[7]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[8]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[9]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[10]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[11]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[12]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[13]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[14]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[16]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukine 12 (IL-12)	TTG68FB	IL12A_HUMAN; IL12B_HUMAN	Not Available	[1]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Biocytogen
• [2] Clinical pipeline report, company report or official report of Amgen
• [3] Clinical pipeline report, company report or official report of Ziopharm Oncology.
• [4] Clinical pipeline report, company report or official report of Celsion.
• [5] Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
• [6] Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
• [7] Clinical pipeline report, company report or official report of EMD Serono.
• [8] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [11] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [14] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [15] National Cancer Institute Drug Dictionary (drug id 740856).
• [16] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [17] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.